おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Repare Therapeutics
company
About
Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.
- 51 - 100
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $68M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$150.50M
Repare Therapeutics has raised a total of
$150.50M
in funding over 2 rounds. Their latest funding was raised on
Sep 4, 2019 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 4, 2019 | Series B | $82.50M | 2 | — | — | Detail |
| Jun 22, 2017 | Series A | $68M | 2 |
Versant Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Repare Therapeutics is funded by 2 investors.
UBS Oncology Impact Fund
and Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
|
Versant Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
